CY1124092T1 - Φυσικως και χημικως σταθερα απο του στοματος γιβινοστατης - Google Patents

Φυσικως και χημικως σταθερα απο του στοματος γιβινοστατης

Info

Publication number
CY1124092T1
CY1124092T1 CY20211100388T CY211100388T CY1124092T1 CY 1124092 T1 CY1124092 T1 CY 1124092T1 CY 20211100388 T CY20211100388 T CY 20211100388T CY 211100388 T CY211100388 T CY 211100388T CY 1124092 T1 CY1124092 T1 CY 1124092T1
Authority
CY
Cyprus
Prior art keywords
oral
physically
chemically stable
givinostatis
formulations
Prior art date
Application number
CY20211100388T
Other languages
English (en)
Inventor
Roberta Artico
Paolo Mascagni
Maria Valmen MONZANI
Silvia PUCCIANTI
Giuseppe Colombo
Original Assignee
Italfarmaco Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Italfarmaco Spa filed Critical Italfarmaco Spa
Publication of CY1124092T1 publication Critical patent/CY1124092T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)

Abstract

Αποκαλύπτονται φυσικώς και χημικώς σταθερά από του στόματος υγρά σκευάσματα Γιβινοστάτης (χλωριούχο διαιθυλ-[6-(4-υδροξυκαρβαμοϋλ-φαινυλκαρβαμοϋλοξυμεθυλ)-ναφθαλιν-2-υλ-μεθυλ]-αμμώνιο), μαζί με μεθόδους για την παρασκευή αυτών. Τέτοια από του στόματος σκευάσματα είναι στη μορφή υδατικών εναιωρημάτων και περιέχουν Γιβινοστάτη ή/και φαρμακευτικώς αποδεκτά άλατα ή/και παράγωγα αυτής, τουλάχιστον έναν παράγοντα διαβροχής ή/και τουλάχιστον έναν παράγοντα απόδοσης πυκνότητας. Τέτοια σκευάσματα είναι κατάλληλα για από του στόματος χορήγηση για συστημική θεραπευτική δράση.
CY20211100388T 2015-11-03 2021-05-07 Φυσικως και χημικως σταθερα απο του στοματος γιβινοστατης CY1124092T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITUB2015A005193A ITUB20155193A1 (it) 2015-11-03 2015-11-03 Sospensioni orali di Givinostat fisicamente e chimicamente stabili
PCT/IB2016/056496 WO2017077436A1 (en) 2015-11-03 2016-10-28 Physically and chemically stable oral suspensions of givinostat

Publications (1)

Publication Number Publication Date
CY1124092T1 true CY1124092T1 (el) 2022-05-27

Family

ID=55410062

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100388T CY1124092T1 (el) 2015-11-03 2021-05-07 Φυσικως και χημικως σταθερα απο του στοματος γιβινοστατης

Country Status (30)

Country Link
US (1) US10688047B2 (el)
EP (1) EP3370697B1 (el)
JP (1) JP6800970B2 (el)
KR (1) KR102603894B1 (el)
CN (2) CN113368044B (el)
AR (1) AR106559A1 (el)
AU (1) AU2016349169B2 (el)
BR (1) BR122024001653A2 (el)
CA (1) CA3002755C (el)
CL (1) CL2018001151A1 (el)
CO (1) CO2018003971A2 (el)
CY (1) CY1124092T1 (el)
DK (1) DK3370697T3 (el)
ES (1) ES2870201T3 (el)
HK (1) HK1254811A1 (el)
HR (1) HRP20210747T1 (el)
HU (1) HUE054123T2 (el)
IL (1) IL258608B (el)
IT (1) ITUB20155193A1 (el)
LT (1) LT3370697T (el)
MX (1) MX2018004505A (el)
NZ (1) NZ741467A (el)
PE (1) PE20181369A1 (el)
PL (1) PL3370697T3 (el)
PT (1) PT3370697T (el)
RS (1) RS61694B1 (el)
RU (1) RU2721396C2 (el)
SI (1) SI3370697T1 (el)
TW (1) TWI727983B (el)
WO (1) WO2017077436A1 (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020283590A1 (en) 2019-05-31 2022-01-20 Viracta Subsidiary, Inc. Methods of treating virally associated cancers with histone deacetylase inhibitors
WO2022088037A1 (zh) * 2020-10-30 2022-05-05 中国科学院深圳先进技术研究院 Sirtinol在制备预防和治疗冠状病毒的药物中的应用
CN114306311A (zh) * 2022-01-14 2022-04-12 同济大学 组蛋白去乙酰化酶抑制剂在制备治疗心脏病的药物中的应用
CN116173003A (zh) * 2023-02-24 2023-05-30 山西医科大学 药物吉维司他在治疗阿尔茨海默病中的用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4169150A (en) * 1975-11-12 1979-09-25 Teijin Limited Benzodiazepine derivatives and pharmaceutical compositions containing said derivatives
DE3902079A1 (de) * 1988-04-15 1989-10-26 Bayer Ag I.m. injektionsformen von gyrase-inhibitoren
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
DE4200821A1 (de) * 1992-01-15 1993-07-22 Bayer Ag Geschmacksmaskierte pharmazeutische mittel
IT1283637B1 (it) 1996-05-14 1998-04-23 Italfarmaco Spa Composti ad attivita' antinfiammatoria ed immunosoppressiva
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
JP4975941B2 (ja) 2000-09-29 2012-07-11 トポターゲット ユーケー リミテッド （ｅ）−ｎ−ヒドロキシ−３−（３−スルファモイル−フェニル）アクリルアミド化合物及びその治療用途
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
JP2005516943A (ja) * 2001-12-20 2005-06-09 ファルマシア コーポレーション 経口投与に適した医薬品懸濁液
CN100445276C (zh) 2002-03-13 2008-12-24 詹森药业有限公司 用作组蛋白去乙酰酶抑制剂的磺酰基衍生物
ITMI20030063A1 (it) 2003-01-17 2004-07-18 Italfarmaco Spa Cloridrato monoidrato dell'estere (6-dietilamminometil-naftalen-2-il)metilico dell'acido (4-idrossicarbammoil-fenil)carbammico.
US7244751B2 (en) 2003-02-14 2007-07-17 Shenzhen Chipscreen Biosciences Ltd. Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
AU2004230889B2 (en) 2003-04-07 2008-03-13 Pharmacyclics Llc Hydroxamates as therapeutic agents
WO2005019174A1 (en) 2003-08-20 2005-03-03 Axys Pharmaceuticals, Inc. Acetylene derivatives as inhibitors of histone deacetylase
ITMI20041347A1 (it) 2004-07-05 2004-10-05 Italfarmaco Spa Derivati di alfa-amminoacidi ad attivita'antiinfiammatoria
EP1781639B1 (en) 2004-07-28 2012-01-25 Janssen Pharmaceutica NV Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
WO2006018814A2 (en) * 2004-08-16 2006-02-23 Ranbaxy Laboratories Limited Oral liquid suspensions of metaxalone
WO2007135362A2 (en) * 2006-05-19 2007-11-29 Norbrook Laboratories Limited Stable aqueous suspension having palatable taste
JP2010502743A (ja) 2006-09-11 2010-01-28 キュリス，インコーポレイテッド 抗増殖薬剤としての多機能性低分子
US8263652B2 (en) * 2007-10-31 2012-09-11 Sk Biopharmaceuticals Co., Ltd. Stabilized pediatric suspension of carisbamate
EP2228054A1 (en) * 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
JP2013509435A (ja) * 2009-10-30 2013-03-14 ヤンセン ファーマシューティカ エヌ．ベー． 長時間作用型注入可能パリペリドンエステルに関連した投与レジメン
IT1397912B1 (it) * 2010-01-28 2013-02-04 Chemi Spa Nuovo polimorfo dell'estere 6-dietilamminometil-2-naftilico dell'acido 4-idrossicarbamoil-fenil-carbammico cloridrato.
WO2011113013A2 (en) * 2010-03-11 2011-09-15 Hemaquest Pharmaceuticals, Inc. Methods and compositions for treating viral or virally-induced conditions
TW201245115A (en) * 2011-01-24 2012-11-16 Chdi Foundation Inc Histone deacetylase inhibitors and compositions and methods of use thereof
CN107007580A (zh) * 2012-02-03 2017-08-04 意大发马克股份公司 用于治疗肌肉萎缩症的化合物
EP2968080B1 (en) * 2013-03-12 2023-05-10 Synedgen, Inc. Oral formulation of polyglucosamine derivatives in combination with a non-fermentable sugar
US9783488B2 (en) * 2013-03-14 2017-10-10 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
WO2015086738A2 (en) 2013-12-11 2015-06-18 Bionor Immuno As Hiv vaccine

Also Published As

Publication number Publication date
BR122024001653A2 (pt) 2024-03-05
PT3370697T (pt) 2021-04-06
RU2018120170A (ru) 2019-12-05
TWI727983B (zh) 2021-05-21
ES2870201T3 (es) 2021-10-26
ITUB20155193A1 (it) 2017-05-03
EP3370697A1 (en) 2018-09-12
CO2018003971A2 (es) 2018-07-19
IL258608B (en) 2022-06-01
HUE054123T2 (hu) 2021-08-30
EP3370697B1 (en) 2021-02-17
CA3002755A1 (en) 2017-05-11
TW201722401A (zh) 2017-07-01
MX2018004505A (es) 2018-09-12
PL3370697T3 (pl) 2021-07-12
JP6800970B2 (ja) 2020-12-16
RS61694B1 (sr) 2021-05-31
AU2016349169A1 (en) 2018-05-17
WO2017077436A1 (en) 2017-05-11
AR106559A1 (es) 2018-01-24
RU2721396C2 (ru) 2020-05-19
SI3370697T1 (sl) 2021-04-30
NZ741467A (en) 2021-07-30
IL258608A (en) 2018-06-28
PE20181369A1 (es) 2018-08-27
BR112018008870A2 (pt) 2018-11-06
AU2016349169B2 (en) 2021-11-11
KR102603894B1 (ko) 2023-11-20
CN108366956B (zh) 2021-09-10
US10688047B2 (en) 2020-06-23
CN108366956A (zh) 2018-08-03
BR112018008870A8 (pt) 2019-02-26
CN113368044A (zh) 2021-09-10
CL2018001151A1 (es) 2018-12-07
US20180311160A1 (en) 2018-11-01
LT3370697T (lt) 2021-06-10
HK1254811A1 (zh) 2019-07-26
HRP20210747T1 (hr) 2021-06-25
CN113368044B (zh) 2023-06-02
RU2018120170A3 (el) 2019-12-05
CA3002755C (en) 2022-10-18
JP2019501116A (ja) 2019-01-17
DK3370697T3 (da) 2021-04-26
KR20180082468A (ko) 2018-07-18

Similar Documents

Publication Publication Date Title
CY1124092T1 (el) Φυσικως και χημικως σταθερα απο του στοματος γιβινοστατης
CY1124669T1 (el) ΑΝΤΙ-ΟΙΣΤΡΟΓΟΝΙΚΑ ΦΑΡΜΑΚΑ ΤΕΤΡΑΫΔΡΟ-1Η-ΠΥΡΙΔΟ[3,4-b]INΔOΛIOY
CY1122966T1 (el) 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου
CY1125292T1 (el) Παραγωγα 6,7,8,9-tetpaϋδpo-3h-πypazoλo[4,3-f iσοκινολινης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου
MY187047A (en) Selective pyy compounds and uses thereof
UY36943A (es) PIRAZOLO[3,4-b]PIRIDIN-6-CARBOXAMIDAS N-SULFONILADAS Y MÉTODO PARA SU USO
CY1122730T1 (el) 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων
CY1123627T1 (el) Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου
TR201901312T4 (tr) Mcl-1 proteinini inhibe eden tetrahidronaftalen türevleri.
HK1247843A1 (zh) 具有受控吸收曲線的用於口服給藥活性劑的製劑
UY35586A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CY1124059T1 (el) Αζαβενζιμιδαζολια και χρηση αυτων ως ρυθμιστες υποδοχεα ampa
CL2015002835A1 (es) Nuevos derivados de piridina
CY1123366T1 (el) Παραγωγα 8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δeκανιου
IT201800001301A1 (it) Formulazioni in gel per la somministrazione orale di farmaci, in particolare nei pazienti disfagici
CY1122892T1 (el) Παραγωγα 3-(καρβοξυμεθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου
CY1122882T1 (el) Παραγωγα 3-(καρβοξυαιθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
ECSP18060834A (es) Derivados de 3-((hetero)aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano
CY1123527T1 (el) Αντιφυματικος παραγοντας
TWI799399B (zh) 吡啶并〔３，４－ｄ〕嘧啶衍生物及其藥學上所容許之鹽
AR108233A1 (es) Composiciones farmacéuticas orales de nicotinamida
HK1243327A1 (zh) 包含螺旋藻和棕櫚酰基乙醇酰胺和/或其鹽或藥用上可接受衍生物的組合及其製劑，用於預防和/或治療過度活化的組織病症
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
PH12018502139A1 (en) Phosphaplatin liquid formulations